Head OfficeClinuvel Pharmaceuticals Limited, Tel: +61 3 9660 4900 |
Swiss OfficeNeuhofstrasse 3D Tel: +41 41 767 4545 |
US Office30 Broad Street Tel: +1 646 480 4810 |
Clinuvel receives a large number of inquiries every day. For a list of frequently asked questions, including information on projected release dates and trial participation please click here.
For more information on Clinuvel’s program for SCENESSE® in vitiligo, please go to http://www.clinuvel.com/vitiligo.
We recently invited Richard Roosenboom to share his experiences as a parent of a child with a rare disease.... Read more...
We recently invited Richard Roosenboom to share his experiences as a parent of a child with a rare disease.... Read more...
Myth 4: I need lots of sun exposure to create vitamin D Vitamin D is a contentious topic in modern... Read more...
Part Four - The impact of Erythro...Mikey's quality of life, like all patients with Erythropoietic Protoporphyria (EPP), is severely affected. Severe pain f... Watch now |
Quick! I need Sunburn Relief! Rem...There are many remedies available to help provide relief from the symptoms of sunburn. Treatment of sunburn can include:... Watch now |
Understanding Vitiligo - Causes &...Vitiligo is a common pigmentary disorder in which the pigment producing cells of the skin (melanocytes) are absent or do... Watch now |
Company HistoryThe technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology an... Read more |
